NOVAVAX
Information

NOVAVAX

ISIN
US6700024010
Ticker
NVAX
ISIN
US6700024010
Ticker
NVAX
New Post

Information

stock large cap
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Employees
791
Industries
Biotechnology & Drugs
Sector
Other

Community

Financials

52W Low
$99.46
52W High
$307.63
Market Capitalization
$15.77B
EBITDA
-$1.03B
Beta
1.2691

Analyst Ratings

Target Price
$260.60
This security is covered by 6 analysts
Buy
4
Hold
2
Sell
0

Activities

Trending